Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo
Go back to Incyte (INCY) Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream as a Treatment for Patients with Vitiligo| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 124.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.65 | 52 Week High | $118.49 | |||
| Open | $124.65 | 52 Week Low | $55.00 | |||
| Day High | $124.65 | P/E | N/A | |||
| Day Low | $124.65 | EPS | $-0.56 | |||
| Volume | 1,432 | |||||
